A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ve303 for Prevention of Recurrent Clostridioides Difficile Infection: The Restorative303 Study
Summary
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).